Compounds > hydroxyurea

hydroxyurea and plerixafor

hydroxyurea has been researched along with plerixafor in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Anagnostopoulos, A; Athanassiadou, A; Batsis, I; Becker, P; Bouinta, A; Constantinou, V; Fassas, A; Jonlin, E; Kaloyannidis, P; Karponi, G; Kotta, K; Papayannopoulou, T; Psatha, N; Stamatoyannopoulos, G; Tahynopoulou, V; Xagorari, A; Yannaki, E; Zervou, F1
André-Schmutz, I; Cavazzana, M; Couzin, C; Delville, M; Félix, T; Gabrion, A; Joseph, L; Lagresle-Peyrou, C; Lamhaut, L; Lefrère, F; Magnani, A; Magrin, E; Miccio, A; Plantier, C; Ribeil, JA; Romano, O; Sadek, H; Stanislas, A; Ternaux, B; Tréluyer, JM; Weber, L1

Reviews

1 review(s) available for hydroxyurea and plerixafor

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

2 trial(s) available for hydroxyurea and plerixafor

ArticleYear
Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2012, Volume: 20, Issue:1

    Topics: Adult; Antigens, CD34; Benzylamines; beta-Thalassemia; Cyclams; Female; Genetic Therapy; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Hydroxyurea; Immunophenotyping; Leukocyte Count; Leukocytosis; Male; Splenectomy; Treatment Outcome; Young Adult

2012
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.
    Haematologica, 2018, Volume: 103, Issue:5

    Topics: Anemia, Sickle Cell; Anti-HIV Agents; Antigens, CD34; Antisickling Agents; Benzylamines; Blood Transfusion; Case-Control Studies; Cells, Cultured; Cohort Studies; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Hydroxyurea

2018

Other Studies

2 other study(ies) available for hydroxyurea and plerixafor

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023